

GENOMIC HEALTH INC
 Form 3
 September 28, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â ROBERTSON REBECCA B		(Month/Day/Year)	GENOMIC HEALTH INC [GHDX]	
(Last)	(First)	(Middle)	09/28/2005	
3000 SAND HILL ROAD,Â BUILDING 4 SUITE 210			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
MENLO PARK,Â CAÂ 94025			<input type="checkbox"/> Director	<input checked="" type="checkbox"/> 10% Owner
(City)	(State)	(Zip)	<input type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below) (specify below)	
			6. Individual or Joint/Group Filing(Check Applicable Line)	
			<input checked="" type="checkbox"/> Form filed by One Reporting Person	
			<input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

Edgar Filing: GENOMIC HEALTH INC - Form 3

				Shares			or Indirect (1) (Instr. 5)	
Series B Preferred Stock	Â (1)	Â (2)	Common Stock	36,036 (3) (4)	\$ (5)		I	By Versant Affiliates Fund I-A, L.P. (6)
Series B Preferred Stock	Â (1)	Â (2)	Common Stock	75,675 (3) (4)	\$ (5)		I	By Versant Affiliates Fund I-B, L.P. (7)
Series B Preferred Stock	Â (1)	Â (2)	Common Stock	32,432 (3) (4)	\$ (5)		I	By Versant Side Fund I, L.P. (8)
Series B Preferred Stock	Â (1)	Â (2)	Common Stock	1,657,657 (3) (4)	\$ (5)		I	By Versant Venture Capital I, L.P. (9)
Series E Preferred Stock	Â (1)	Â (2)	Common Stock	4,728 (4) (10)	\$ (11)		I	By Versant Affiliates Fund I-A, L.P. (6)
Series E Preferred Stock	Â (1)	Â (2)	Common Stock	9,929 (4) (10)	\$ (11)		I	By Versant Affiliates Fund I-B, L.P. (7)
Series E Preferred Stock	Â (1)	Â (2)	Common Stock	8,890 (4) (10)	\$ (11)		I	By Versant Side Fund I, L.P. (8)
Series E Preferred Stock	Â (1)	Â (2)	Common Stock	449,265 (4) (10)	\$ (11)		I	By Versant Venture Capital I, L.P. (9)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ROBERTSON REBECCA B 3000 SAND HILL ROAD BUILDING 4 SUITE 210 MENLO PARK, CA 94025	Â	Â X	Â	Â

Signatures

/s/ Robin Praeger,
Attorney-in-Fact

09/28/2005

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are exercisable immediately.

Edgar Filing: GENOMIC HEALTH INC - Form 3

- (2) These securities do not have an expiration date.
- Does not include shares of Common Stock that may be issued to the Reporting Persons if the conditional dividend of shares of Common Stock declared by the Issuer's Board of Directors on September 8, 2005 is distributed upon the closing of the Issuer's initial public offering (the "IPO") in the event the price per share of the Issuer's Common Stock sold in the IPO is \$11.40 or greater (the "Conditional Dividend").
- (3)
- Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- (4)
- Upon consummation of the IPO, every 3 shares of Series B Preferred Stock will convert into 1 share of Common Stock.
- (5)
- The shares owned by Versant Affiliates Fund I-A, L.P. ("VAF-IA"). The general partner of VAF-IA is Versant Ventures I, LLC ("VVI").
- (6)
- The shares owned by Versant Affiliates Fund I-B, L.P. ("VAF-IB"). The general partner of VAF-IB is VVI.
- (7)
- The shares owned by Versant Side Fund I, L.P. ("VSF"). The general partner of VSF is VVI.
- (8)
- The shares owned by Versant Venture Capital I, L.P. ("VVC"). The general partner of VVC is VVI.
- (9)
- Does not include additional shares of Common Stock that will be issued to the Reporting Persons upon consummation of the IPO as a result of either the Conditional Dividend or the Increased Conversion Rate (as defined in footnote 11 below).
- (10)
- Upon consummation of the IPO, every 3 shares of Series E Preferred Stock will be converted into 1 share of Common Stock; provided, however, if the price per share of shares sold in the IPO is less than \$11.40, the conversion rate will be 1.128 shares of Common Stock for every 3 shares of Series E Preferred Stock (the "Increased Conversion Rate").
- (11)

Â

Remarks:

General Remarks: This report is being filed jointly with the report filed by Versant Venture Capital I-A, L.P., Versant Affiliates Fund I-B, L.P., Versant Side Fund I, L.P., Versant Ventures I, LLC, Â M.D., William J. Link, Barbara N. Lubash and Donald B. Milder as of the date hereof and related registration of the Issuer's Common Stock under Section 12 of the Securities Exchange Act of 1934 because the number of joint filers exceeded the maximum number of filers permitted by the EDGAR

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.